| WELCOME TO THE LYMPHOMA FOUNDATION | |||
|
BOARD MEMBERS
and SPECIAL
MEMORIAL NOTICES
EVENTS |
Members of the Board and Friends
MISSION STATEMENT
OF THE LYMPHOMA FOUNDATION LYMPHOMA FOUNDATION NEWS RECENT EVENTS: THE FOURTH ANNUAL MORTIMER J. LACHER LECTURE sponsored by the MSKCC Division of Hematologic Oncology of the Department of Medicine was held in the main auditorium of the Zuckerman Research Building of the Memorial Sloan Kettering Cancer Center... as part of MEDICAL GRAND ROUNDS on FRIDAY May 17, 2013 starting at 8AM. The keynote scientific lecture of this Lacher Day celebration was delivered by Dr. Marcel R. M. van den Brink, MD, PhD Head of the Division of Hematologic Oncology and an Attending Physician in the Adult Allogeneic Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center, the Alan Houghton Professor in Immunology of the Sloan-Kettering Institute, and Professor of Medicine and Immunology at Weill Medical College of Cornell University. Dr. van den Brink's laboratory has made important discoveries regarding graft-versus-host disease (including the role of T cell homing, innate lymphoid cells and intestinal stem cell regeneration), graft-versus-tumor activity (such as post-transplant tumor vaccines and the role of TRAIL in donor T cell-mediated graft-versus-tumor effects), and post-transplant immune reconstitution (adoptive therapy with “off-the-shelf” T cell precursors, Interleukin-22 and thymic stroma regeneration). This work is being translated into clinical trials involving Interleukin-7, Keratinocyte Growth Factor, Leuprolide and T cell precursors to enhance post-transplant T cell recovery. In addition... on Friday May 17, 2013 a meeting was held in the Mortimer Zuckerman Research Building of MSKCC to further celebrate Lacher Day as the five Lacher Fellows of the past year (2012-2013) presented their research. To date…beginning in 1983 with the support of the Lymphoma Foundation…127 Lacher Fellows have been able to conduct cancer research under the guidance of senior Sloan Kettering and Memorial Hospital staff members… for one, two or three years of post graduate research experience. The day after the Grand Rounds meeting… The 16th ANNUAL BRIAN ROONEY RUN/WALK in Central Park, NYC... a fund raising event for the Lymphoma Foundation in honor and memory of Brian Rooney was held on SATURDAY AT 10AM May 18, 2013 and after the Race...THE POST RACE PARTY (included in the Entrance Fee) was held at RATHBONE'S PUB & GRILL 1702 2nd Ave, New York 10128 (At 88th St) A key group of volunteers, in addition to Tricia and Andrew Bresnahan, give their personal talents and time and money to set up the “Run” in the Park. They are: Erin Leixner, Rosemary Maxfied, Emily Fleischer, Stu and Eunice Patchen, Frank Bernabei, Lyle Chernoff, Erin and Chris Moriarty, Frank Cipolla, Stephanie Fallon, Sara Cooney, Jack Cooney and Aimee Sprogis helps every year with putting together the flyer. This year Barb Schemera designed the t-shirt. And each year Annie and Kevin McKenna have arranged for the venue and the free food at the Party after the Run for all participants. The Lymphoma Foundation pays for the event liability insurance plan required by the Parks Department and sends out announcements of the Run to its own list of potential participants. The spirit and generosity of the volunteers over the past 16 years is amazing! And we thank them for their support of cancer research… especially in this difficult economic time. PAST EVENTS - THE THIRD ANNUAL MORTIMER J. LACHER LECTURE sponsored by the MSKCC Division of Hematologic Oncology of the Department of Medicine was held in the main auditorium of the Rockefeller Research Building of the Memorial Sloan Kettering Cancer Center... as GRAND ROUNDS on FRIDAY May 18, 2012 starting at 8AM. Dr. George Bosl, Chairman of the Department of Medicine, acted as host of the program and introduced Dr. Lacher and then Dr. Brian Druker, the guest Lecturer.
Dr. Brian Druker, a co-discoverer and
developer of Imatinib (Gleevec), a recipient of the Lasker Award and
many other honors for this groundbreaking leukemia
research...reviewed his role in the discovery of Imatinib and its
introduction into clinical trials for the treatment of chronic
granulocytic leukemia. The 15th ANNUAL BRIAN ROONEY RUN/WALK in Central Park, NYC... was held on Saturday May 19, 2012 and after the race... the post race party was held at the East End Tavern on First Avenue. The 14th ANNUAL BRIAN ROONEY RUN/WALK in Central Park, NYC was held on Saturday, May 21, 2011.
THE LACHER FELLOWS LYMPHOMA/ HEMATOLOGY/ RADIATION ONCOLOGY RESEARCH CONFERENCE of the Memorial Sloan Kettering Cancer Center (MSKCC) was held on Friday morning, May 20, 2011, in the Zuckerman Research Building
THE SECOND ANNUAL MORTIMER J. LACHER LECTURE sponsored by the MSKCC Division of
Hematologic Oncology of the Department of Medicine
was held on Friday afternoon, May 20, 2011, in the Zuckerman
Research Building... |
||
|
COMPLICATIONS OF SURVIVAL BREAST CANCER
AND MORE ABOUT HEART AND
ARTERY DISEASE AFTER RADIATION THERAPY |
YOUR RESEARCH DOLLARS AT WORK ----- The following research was supported with Lymphoma Foundation grants:
Janus kinase 2 (JAK2) as a
Therapeutic Target in Graft-versus-Host Disease Janus kinase 2 (JAK2) is a principle regulator of cytokine signaling in inflammation. We have demonstrated that selective JAK2 inhibition with TG101348 induces allotolerance without impairing viral immunity in vitro. JAK2 inhibition also extends survival in a mouse graft-versus-host disease (GvHD) model, without compromising engraftment. The immunosuppressive effects of JAK2 inhibition are primarily T cell-dependent, though JAK2 is required for full phenotypic maturation of monocyte-derived dendritic cell (moDC). JAK2 inhibition preserves baseline levels of allogeneic resting, central memory, and effector memory T cells, while suppressing CD25, a marker of alloreactivity, in the central and effector memory compartments. JAK2 blockade does not impair regulatory T cell (Treg) expansion, and enhances the Treg:effector ratio in favor of the Tregs. JAK2 inhibition reduces the production of proinflammatory cytokines, and impairs the expansion of alloreactive T helper 1 (Th1) and T helper 17 (Th17) cells. TG101348 is a highly selective JAK2 inhibitor, which ablates JAK2 signaling and preserves JAK3 signaling in T cells. JAK2 represents a biologically relevant target in preventing and treating GvHD and allograft rejection, without broader immune impairment. Engineering Antigen Receptors for T-Cell Immunotherapy
Marcela Maus, MD Mentor: Michel Sadelain, MD, PhD Over the past decade, the adoptive transfer of T cells has emerged as an effective therapy in some patients with hematological malignancies or melanoma. To be more broadly applicable, tumor-reactive T cells would have to be easily accessible and expandable from any patient. Recently, several groups have explored retroviral transduction of autologous T cells with molecularly designed antigen-specific receptors, either based on native T cell receptors, or chimeric antigen receptors, or CARs. The goal of this project is to develop an approach to target T cells to an intracellular antigen, focusing on NY-ESO-1 expressing tumors such as melanoma or myeloma. We have chosen NYESO1 as a target antigen because of its frequent expression in a wide variety of tumors yet restricted expression in normal tissues. The central hypothesis is that an intracellular antigen can be targeted by retroviral transduction of T cells with either a chimeric antigen receptor or a T cell receptor that has been engineered to avoid mispairing. We are also comparing a chimeric antigen receptor that is based on a TCR-like antibody that is specific for HLA-A2/NYESO1 peptide to a panel of the engineered TCRs with the same specificity. In the past year, Dr. Maus has designed and generated retroviral vectors with a panel of constructs for the engineered T cell receptors, and has generated preliminary data showing that an antibody-based chimeric antigen receptor can be targeted toward an intracellular tumor antigen; however, although the scFv-based CAR was very specific for HLA-A2 bound to NYESO peptide when it was generated in soluble form (i.e., an antibody), we have found that when the same scFv is membrane-bound as part of a CAR, there is some peptide-independent binding to HLA-A2. Based on the crystal structure of the antibody binding to HLA-A2/peptide, a panel of mutants has been generated in the scFv in an attempt to decrease binding to the HLA-A2 molecule; testing of these mutants ex vivo and in vivo is underway.
THE ANNUAL MORTIMER J. LACHER FELLOWS RESEARCH CONFERENCE WAS HELD IN THE ZUCKERMAN RESEARCH
BUILDING
OF THE MEMORIAL SLOAN KETTERING CANCER CENTER Introduction: Craig Moskowitz, MD
PRESENTATIONS: Brian Betts, MD Mentor: James Young, MD Janus kinase 2 (JAK2) as a Therapeutic Target in Graft-versus-Host Disease Marcela Maus, MD Mentor: Michel Sadelain, MD, PhD Engineering Antigen Receptors for T-Cell Immunotherapy Jae Park, MD Mentor: Renier Brentjens, MD, PhD Treatment of B-cell Leukemia with CD19-targeted Genetically Modified T-cells: The Next Step Alan Hanash, MD, PhD Mentor: Marcel van den Brink, MD, PhD Novel Cytokine Pathways in Graft vs. Host Disease Christopher Barker, MD Mentor: Joachim Yahalom, MD, FACR Total Body Irradiation: Past, Present and Future Concluding Remarks:
Mortimer J. Lacher, MD, FACP THE SECOND ANNUAL MORTIMER J. LACHER LECTURE
Was held on
Friday May 20, 2011 Guest Lecturer: Kenneth
Kaushansky, M.D., M.A.C.P. Stony Brook University
Raymond L. Comenzo, MD is the Director, Blood Bank and Stem Cell Processing Laboratory, Department of Medicine, Hematology/Oncology Divisions of the Tufts Medical Center, Boston, MAAndrew D. Zelenetz, MD, PhD, is the Chief of the Lymphoma Service, Division of Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY Marcel R. M. van den Brink, MD, PhD, holds the Alan N. Houghton Chair and is the Head, Division of Hematologic Oncology at the Memorial Sloan Kettering Cancer Center, New York, NY
DR. RANDY GASCOYNE WAS THE GUEST LECTURER AT THE FIRST ANNUAL MORTIMER J. LACHER LECTURE OF THE MEMORIAL SLOAN KETTERING CANCER CENTER HELD IN THE ZUCKERMAN RESEARCH BUILDING - MAY 26, 2010
12:30 – 1:30PM in ZRC-105
Randy D. Gascoyne, M.D., Guest Lecturer Dissecting Hodgkin Lymphoma Biology to Better Understand Treatment Failure
Clinical Professor of Pathology, University of British Columbia Hematopathologist, BC Cancer Agency & the BC Cancer Research Center Research Director, Center of Lymphoid Cancers BCCA
FOLLOW THIS LINK TO PREVIOUS LACHER FELLOWS RESEARCH CONFERENCES
ON SATURDAY MAY 22nd 2010 ...
A FAMILY FRIENDLY EVENT
RESEARCH SUPPORTED BY LYMPHOMA FOUNDATION GRANTS: A
REPORT IN SEPTEMBER 2009 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SIGNALING STUDY: “This is a collaboration [with myself] and Drs. van den Brink (Immunology) and Gregoire Altan-Bonnet (Computational Biology) [Memorial Sloan Kettering Cancer Center] .We have so far screened 60 samples from patients with CLL with known prognostic features… and 10 healthy individuals as control. Thawed peripheral blood mononuclear cells from patients and healthy volunteers are stimulated with anti-IgM antibody to cross-link the B cell receptor (BCR) and initiate signaling events. The cells are then fixed and permeabilized. A mixture of surface and intracellular antibodies recognizing lymphocyte markers and phosphorylated (activated) signaling proteins is then used to establish the level of activation in CD20+/CD5+ B cells in different patients (CD20+ cells in normal volunteers). We have been able to show both a higher responsiveness to the B cell Receptor (BCR) stimulation in CLL B cells compared to normal B cells and a high degree of variability among patients. We are trying to establish if there is a correlate between this variability and the prognostic features of each patient. For this purpose we plan to create software that will allow us to analyze the substantial amount of data generated by flow cytometry and the available clinical data and provide an easy graphic representation.” DIFFICULTY IN THE DEVELOPMENT OF A LYMPHOMA VACCINE: UPDATE SEPTEMBER 2009: regarding the CD20 DNA vaccine clinical trial: “This protocol is a dose-escalation study of a heteroclitic DNA vaccine, given five times at three week intervals, using a fragment of mouse CD20 DNA as the immunogen. Since my last report, this study has undergone significant expansion of the eligibility criteria in order to improve accrual, which, however, continues to be low. Currently, eligible patients must have had at least one prior treatment with chemo- radiation- or immunotherapy. All histologies except Burkitt’s lymphoma and lymphoblastic lymphoma are allowed. Prior autologous stem cell transplant is now allowed. Because of concerns of inducing permanent B cell depletion, the FDA has requested that each of the first three patients (pre-level 1 cohort) be enrolled in a staggered manner and receive a significantly lower DNA dose compared to the three cohorts of the study in order to be monitored closely for toxicities. Their circulating B cells will be serially measured by flow cytometry at established time points before, during and after the treatment period. Our first patient received 4 out of 5 planned vaccinations due to progression of disease. No depletion of B cells was observed. The second patient withdrew from the study before receiving the first vaccination. We are in the process of screening 2 more potential patients for enrollment this month.” LYMPHOMA FOUNDATION SUPPORTED RESEARCH ACCOMPLISHMENTS
IT TAKES TIME TO EFFECT CHANGE BUT AS NOTED BELOW... LYMPHOMA FOUNDATION GRANT SUPPORT FOR PATIENT ORIENTED RESEARCH LED TO A MAJOR CHANGE IN HODGKIN’S DISEASE TREATMENT
SPEARHEADED BY THE RESEARCH
“Results of a prospective randomized
clinical trial of doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD
alone for stages I, II, and IIIA nonbulky Hodgkin disease”
published
in the journal
Blood,
1 December 2004, Vol. 104, No. 12, pp. 3483-3489,
a
major change of treatment by many medical oncologists occurred.
|
||
IMPORTANT
DATA
:
ABOUT YOUR VITAMIN D REQUIREMENT
CONCERNING YOUR NEED FOR A HIGHER DAILY INTAKE
OF VITAMIN D
AND CAUTION WITH REGARD TO THE NEW SHINGLES
(HERPES ZOSTER) VACCINE
|
|||
|
MORE INFORMATION ABOUT VITAMIN D JULY 2008 FROM: JAMA NEWS in the Journal of the American Medical Association LOW VITAMIN D LINKED TO INCREASE HEART DEATH “The weight of evidence connecting low vitamin D levels with poor health is getting heavier. One study published in the June 9 Archives of Internal Medicine linked low levels of this vitamin in men to an increased risk of myocardial infarction. The other, in the June 23 issue of the same journal, found that being deficient in this vitamin more than doubled the risk of death from any cause. "The evidence is just becoming overwhelming," said Dr. Harald Dobnig, lead author on the second paper and professor of internal medicine at the Medical University of Graz in Austria. These are the latest studies to identify low vitamin D as a significant health risk. Additional analyses completed on the cohort studied by Dr. Dobnig and [studies] due to be published in the future show that vitamin D status also influences the risk of cancer and stroke.” AND a cautionary note: “Also, while compelling evidence appears to support the notion that low vitamin D is unhealthy, less data exist to signal that increasing consumption will improve health status. Studies investigating this premise are forthcoming. Researchers are pursuing vitamin D supplementation as possible treatments for a wide range of health issues from obesity to diabetes to various forms of cancer.”
OCTOBER 13, 2008 Doubling of Vitamin D for Children Is Urged as reported in an ASSOCIATED PRESS release
“CHICAGO (AP) — The country’s leading group of pediatricians is
recommending that children receive double the usually suggested
amount of vitamin D because of evidence that it might help prevent
serious diseases.” “The new advice is based on mounting research
about potential benefits from vitamin D besides keeping bones
strong, including suggestions that it might reduce the risk for
cancer, diabetes and heart disease. But the evidence is not
conclusive, and there is no consensus on how much vitamin would be
needed for disease prevention.” |
|||
|
PREVIOUS LYMPHOMA FOUNDATION NEWS -
MULITPLE MYELOMA TREATMENT ENTERS A NEW PHASE:
IN AUGUST 2007 RAYMOND L. COMENZO, MD REPORTED TO
THE LYMPHOMA FOUNDATION: “Regarding
our current clinical research, we have three protocols open and
accruing that the Lymphoma Foundation is helping to support. The
first is a phase II trial that employs Bortezomib with multiple
other agents for patients with newly diagnosed high-risk multiple
myeloma. The second and third employ Bortezomib for patients with
systemic AL-amyloidosis. One is a phase II trial for newly diagnosed
patients who receive a stem cell transplant and then adjuvant
therapy with Bortezomib and dexamethasone if there is persistent
plasma cell disease. The other is a phase I/II trial for previously
treated patients with relapsed or progressive disease. This trial is
just entering the phase II level. Significant activity was seen
in the phase I portion of the study (25% complete response rate) as
reported at ASCO in June 2007. Clinical research in myeloma is
entering an era of more drugs and increasing complexity. At Memorial
Sloan Kettering Cancer Center our myeloma group is opening trials
for patients with advanced disease employing Bortezomib with 17-AAG
in one case and with Avastin in another. We are seeking approval for
a Bortezomib-based phase II trial as initial therapy in
non-transplant myeloma patients. We also have a phase II
investigator-initiated trial opening soon that uses the new agent
Lenalidomide (Revlimid) and Rituxan for CD20+ myeloma… “We depend
on the help of the Lymphoma Foundation and other supporters to allow
us to stay in the forefront of clinical research in myeloma asking
the hard question -- is early stem cell transplant better?
It is important to note that all the
investigator-initiated trials have translational objectives that are
laboratory-based. The Lymphoma Foundation's support is critical for
these efforts.”
JULY 2007 - DEVELOPING A CANCER VACCINE AGAINST LYMPHOMA —
CONTINUING WORK TOWAD A PATIENT ORIENTED CLINICAL TRIAL OF A CANCER
VACCINE (1) Guevara-Patino, J.A., M.E. Engelhorn, M.J. Turk, C. Liu, F. Duan, G. Rizzuto, A.D. Cohen, T. Merghoub, J.D. Wolchok, and A.N. Houghton. 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 116:1382-1390. (2) Houghton, C.S., M.E. Engelhorn, C. Liu, D. Song, P. Gregor, P.O. Livingston, F. Orlandi, J.D. Wolchok, J. McCracken, A.N. Houghton, and J.A. Guevara-Patino. 2007. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine, in press.” PART II: JULY 2007 TO THE LYMPHOMA FOUNDATION: BY Maria Lia Palomba, MD and Alan N. Houghton, MD: Regarding a clinical trial of anti-CD20 DNA vaccine in patients with relapsed or refractory lymphoma: “We have developed a clinical trial for patients with relapsed or refractory lymphoma, and we are in the final stages of attaining approval to begin the trial, which we anticipate will be in the early fall 2007, pending no request to changes to the protocol:The protocol was approved by the Department of Medicine Steering Committee, Research Council and passed initial IRB review at MSKCC (along with several other committees). The protocol was approved by the Recombinant DNA Advisory Committee of the NIH after public review and following minor modifications. A pre-IND teleconference with the FDA raised only minor concerns. Toxicity studies in rabbits are now completed and show no evidence of toxic effects.The CD20 vaccine to be used in the proposed study has been manufactured and vialed, and the GMP-manufactured product is being stored at MSKCC in the Pharmacy Department and ready for use following protocol approval by the FDA. An IND application was recently submitted to the FDA. The protocol is also simultaneously undergoing final reviews by the MSKCC Institutional Biosafety Committee and the Institutional Review Board. Bringing this vaccine to clinical trials has been challenging but we are delighted to report that the clinical trial should begin in the next few months.”
|
|||
|
NOTEWORTHY
INFORMATION: About
the development of second cancers and heart disease after successful
lymphoma treatment... Women must do everything possible to try to detect the development of a second primary breast cancer at the earliest stage that may still be curable... by diligent attention to obtaining their mammograms (see data concerning the value of mammography). Second cancers induced primarily by a late effect of radiation is a continuing dilemma that is not easily solved. On the one hand radiation therapy can confer a long life free of the primary lymphoma and then, much later in life, it is the source of the development of a wide variety of second cancers that are still very difficult to treat. The death of a
young man from colon cancer 16 years after he was first treated for
Hodgkin's disease highlights this ongoing clinical
problem.
YOUR ATTENTION PLEASE... PRESERVING LONG LIFE BY ADDING A STATIN TO YOUR 'DIET' Ask your doctor to check your LDL-Cholesterol. It is more important than your total cholesterol. New data indicates that the 'old' guidelines may have to be revised and your goal should be an LDL-Cholesterol of 70 (seventy) or lower. For more information see the LYMPHOMA FOUNDATION NEWSLETTERS concerning Editorials about the value of statin medication, "THE IDEAL CHOLESTEROL: Lower is better" and the dilemma concerning the best treatment for Follicular Lymphomas and summaries of work supported in part by Lymphoma Foundation grants. ALSO GO TO: HEART and ARTERY CHANGES AFTER TREATMENT and review Commentary by Clinical and Basic Research Scientists receiving grant support from the Lymphoma Foundation to help you appreciate their efforts and accomplishments regarding vaccine therapy, monoclonal antibody treatments, the role of genetics in preventing or causing cancer, advances in the treatment of ovarian cancer, stem cell transplantation, radiation and chemotherapy to treat Hodgkin's disease, the non-Hodgkin's lymphomas, leukemia and myeloma and the unique role of the telomere in aging and cancer causation. FOLLOW THIS LINK TO THE LACHER FELLOWS RESEARCH CONFERENCES THE 10TH ANNUAL BRIAN ROONEY RUN/WALK IN CENTRAL PARK, NEW YORK CITY WAS HELD SATURDAY MORNING MAY 19, 2007 and once again the Run was attended by a wonderful group of 'runners' and 'walkers'. After the Run at Snapper Creek Tavern a delicious luncheon buffet was enjoyed by the participants Proceeds from the run will be supplemented by the Lymphoma Foundation to distribute grants for the support of basic lymphoma cell research, monoclonal anti-body research for non-Hodgkin's lymphoma and continuing clinical trials and improvements in stem cell transplantation for relapsing lymphoma
|
|||
    The runners got off to a good start while young Colin and Andrew Bresnahan wondered who would come in first... The first woman runner seemed to be flying toward the finish line leaving the pack far behind while some 'walkers' and their dog arrived in a more leisurely manner. Read more about the Rooney Run/Walk in Central Park |
|||
|
|
|||
|
INFORMATION FOR PERSONS WHO WANT TO LEARN ABOUT HUMAN RESEARCH CLINICAL TRIALS Many individuals want to know where to find information concerning patient research trials: Just click on the ClinicalTrials.gov link and type in the subject you are looking for. For instance: When you reach the CLINICAL TRIALS website type in the words LYMPHOMA VACCINE and you will be directed to the current lymphoma vaccine trials. |
|||
|
|
FOLLOW THIS LINK TO
HUMAN RESEARCH TRIALS |
||
|
|
|||
| ATTENTION WOMEN SURVIVORS OF HODGKIN'S DISEASE |
LOWER YOUR CHOLESTEROL LEVELS
WITH STATIN MEDICATIONS:
CHECK OUT DATA
ON THE HEART PAGE
AND THE SEPTEMBER 2005 NEWSLETTER |
American Society of Hematology and American Society of Clinical
Oncology |
|
|
WHAT YOU SHOULD KNOW ABOUT BREAST CANCER
AND THE NEED FOR EARLY MAMMOGRAPHIC SURVEILLANCE
SUPPORT CANCER RESEARCH
MEMORIAL TRIBUTES |
ATTENTION
ALL PERSONS AND ESPECIALLY THOSE LYMPHOMA PATIENTS WHO RECEIVED RADIATION THERAPY THERE IS A WAY TO PREVENT CORONARY ARTERY DISEASE THAT LEADS TO HEART ATTACKS AND PREVENT BLOOD VESSEL DAMAGE FROM ATHEROSCLEROSIS... THAT MAY LEAD TO A STROKE BY LOWERING YOUR CHOLESTEROL LEVELS WITH STATIN MEDICATIONS: CHECK OUT THE DATA ON THE HEART PAGE SPECIAL HONORS
2006-2007
SPECIAL HONORS
- 2004 - 2005 |
DURING
2007-2008
LYMPHOMA
FOUNDATION RESEARCH GRANTS WERE AWARDED FOR:
►New
trials of chemotherapy regimens using bendamustine, a
chemotherapeutic agent that has demonstrated activity in patients
with chemo-resistant and rituximab-resistant disease.
DURING
2005-2006
LYMPHOMA
FOUNDATION RESEARCH GRANTS WERE AWARDED FOR: ►IMRT - INTENSITY MODULATED RADIATION THERAPY - Dr. Joachim Yahalom - MSKCC ►SPECIAL STUDY OF THE RELATIONSHIP OF RADIATION THERAPY TO BREAST CANCER - Dr. Joachim Yahalom - MSKCC
►RESEARCH OF AGING and NF1 --
NEUROFIBROMATOSIS -Dr. Christopher Counter - Duke University - Dr. Kenneth
Offit - and Dr. Suresh Jhanwar - Memorial Sloan Kettering Cancer Center
SPECIAL
JUNE
2009MEETING
NATIONAL RESEARCH
MEETINGS |
|
|
The Lymphoma Foundation supports outstanding
▲SCIENTISTS
who have contributed valuable academic and practical ▲RESEARCH as evidenced by their peer-reviewed ▼PUBLICATIONS. The
▲
BOARD
of the Lymphoma Foundation has also reached
out Through the Marie Project Initiative of the Lymphoma Foundation special efforts are supported that will lead to the prevention and cure of ▲BREAST CANCER ▲HEART DISEASE - AND THE IMPORTANCE of CONTROLLING YOUR CHOLESTEROL |
|||
|
CALL THE LYMPHOMA FOUNDATION AT
|
|||
|
You can also write to the Lymphoma Foundation at the following address: The Lymphoma Foundation |
|||
|
▲SCIENTISTS ▲RESEARCH ▲ EVENTS ▲ BOARD ▲ FELLOWS ▲BREAST CANCER HEART DISEASE ▼PUBLICATIONS ▼CONTACT US
The Lymphoma Foundation is a nationwide not for profit foundation dedicated to funding clinical and basic laboratory cancer research and applying the knowledge developed by the clinician scientists to the general welfare and education of all cancer patients. © Copyright THE LYMPHOMA FOUNDATION All rights reserved |
|||
A special memorial note
about David Klein who succumbed to an uncontrollable colon cancer at
the age of 38, sixteen years after he was first treated for
Hodgkin's disease... may be found among the
SPECIAL MEMORIAL NOTICES on the 
The
Ninth Annual Lymphoma Foundation Brian Rooney Run/Walk was held on
Saturday May 20th, 2006 in Central Park, New York City and was
attended by an enthusiastic group of 'runners' and 'walkers'.
After the Run they all enjoyed a delicious luncheon buffet at
Snapper Creek. 
The
hand of tragedy reached out and ended a life of caring and generosity with
the sudden death of Edward Spiegel... another dedicated Board Member
of the Lymphoma Foundation ♥♥♥
